Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial of Pegcantratinib in Patients with Psoriasis

Trial Profile

A Phase III Trial of Pegcantratinib in Patients with Psoriasis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals

Most Recent Events

  • 05 Aug 2019 According to a Sienna Biopharmaceuticals media release, the company will continue to explore capital raising to enable the initiation of the planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib; CT profile 232992 and 305470), in addition to exploring a wide range of financial and strategic alternatives.The company does not intend to initiate these planned phase 3 trials of SNA-120 until the company secures sufficient additional capital.
  • 10 Jun 2019 According to a Sienna Biopharmaceuticals media release, first patient enrollment is anticipated in the second half of 2019.
  • 20 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top